Clinical Trial Update: Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial of Actinium-225 labeled anti-CEA antibody (Ac225-DOTA-M5A) for advanced or metastatic cancers is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Ac225-DOTA-M5A (Actinium-225 labeled anti-CEA antibody M5A)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Advanced Cancer, Metastatic Cancer | Phase 1 | Status: SUSPENDED